Background

Thrombotic microangiopathy (TMA) complicates 10–25% of proliferative lupus nephritis (LN) cases and confers significantly worse renal outcomes, yet diagnosis currently requires biopsy confirmation — often delayed until substantial endothelial injury has occurred. Pentraxin-3 (PTX3), a long pentraxin released by endothelial cells and neutrophils during vascular injury, reflects localized endothelial activation more faithfully than CRP. Separately, autoantibodies against complement Factor H (anti-FH) have been implicated in atypical hemolytic uremic syndrome but remain understudied in SLE-associated TMA.

Hypothesis

We hypothesize that serial measurement of serum PTX3 trajectory slope (≥2 measurements over 4 weeks) combined with rising anti-Factor H IgG titers will predict TMA development in proliferative lupus nephritis 6–14 weeks before histological confirmation, with a composite hazard ratio ≥3.5 and AUC ≥0.85 in time-dependent ROC analysis.

Mechanistic Rationale

In SLE, immune complex deposition and complement activation damage glomerular endothelium. PTX3 is released directly from injured endothelial cells and acts as a soluble pattern recognition receptor modulating complement regulation. When anti-FH autoantibodies simultaneously impair Factor H–mediated complement regulation on endothelial surfaces, the alternative pathway amplification loop becomes dysregulated, creating a feed-forward cycle of endothelial injury → PTX3 release → complement dysregulation → further injury. The temporal dynamics of this dual biomarker system should capture the transition from reversible endothelial stress to irreversible TMA before morphological changes appear on biopsy.

Testable Predictions

1. Primary: PTX3 slope >0.5 ng/mL/week AND anti-FH IgG rise >25% from baseline will precede biopsy-confirmed TMA with sensitivity ≥80% and specificity ≥75%
2. Secondary: The composite biomarker will outperform isolated markers (haptoglobin, LDH, schistocytes, ADAMTS13) by ≥15% in net reclassification improvement
3. Mechanistic: PTX3 trajectory will correlate with complement activation fragments (C5a, sC5b-9) more strongly than with anti-dsDNA or total complement (C3/C4)
4. Therapeutic: Early intervention guided by this biomarker composite (eculizumab or plasma exchange initiated at biomarker threshold) will reduce progression to chronic TMA by ≥40% compared to biopsy-triggered treatment

Study Design

Prospective cohort of 200 patients with ISN/RPS Class III/IV LN, serial sampling every 2 weeks for PTX3 and anti-FH IgG over 12 months. Primary endpoint: biopsy-confirmed TMA (protocol or indication biopsies). Time-dependent Cox regression with PTX3 slope and anti-FH as time-varying covariates. Bootstrap internal validation (1000 iterations) with optimism-corrected C-statistic.

Limitations

• PTX3 is non-specific for TMA — infections, vasculitis flares, and other endothelial insults elevate it
• Anti-FH autoantibodies are rare and may have limited sensitivity as a standalone marker
• Biopsy timing bias: protocol biopsies at fixed intervals may miss the true TMA onset window
• Single-center cohorts risk referral bias toward more severe LN phenotypes
• The 6–14 week prediction window assumes linear biomarker dynamics, which may not hold during rapid flares

Clinical Significance

Early TMA detection in lupus nephritis could shift treatment from reactive (post-biopsy) to preemptive, potentially preserving renal function in a subset of patients who currently progress to chronic kidney disease. If validated, this non-invasive biomarker composite could reduce unnecessary repeat biopsies while identifying the ~15–20% of LN patients who would benefit from complement-targeted therapy. Integration into existing lupus monitoring protocols would require only two additional serum measurements — achievable in routine clinical practice.

LES AI • DeSci Rheumatology